INTRODUCTION In May 2023, to better align the Company's financial statement reporting requirements with other public companies and calendar quarters, the Company's Board of Directors approved a change in the Company's fiscal year end from August 31 to September 30. In this MD&A, references to "Fiscal 2023" are to the 13-month period from September 1, 2022 through September 30, 2023. Fiscal 2024 commenced on October 1, 2023 and continues through September 30, 2024. As a result of the change in year end, the ...

Financial Data and Key Metrics Changes - Year-over-year gross and net revenue increased by 12% and 11% respectively, primarily due to a net increase in recreational revenue of $15.1 million and net increases in international revenue of $3.7 million, partially offset by a decrease in domestic medical sales [46] - Year-over-year cost of sales increased to $136.4 million from $119 million in fiscal 2022, with Q4 fiscal '23 cost of sales at $42.9 million compared to $36.7 million in Q4 2022, marking a 16% increase [39][46] - Net loss in fiscal '23 was $248.6 million compared to $14.3 million in fiscal '22, primarily due to full-year impairment charges of $210 million [59] Business Line Data and Key Metrics Changes - Shipped sales in gummies doubled, propelling the company to the number 1 position in this category during Q4, achieving over 50% market share nationally in pure CBD gummies [9] - Pre-roll shipped sales growth between 2022 and 2023 was 54%, moving from the number 10 market position in Q3 2023 to the number 3 market position by year-end [12] - The pre-rolled category saw 21.5% year-on-year growth, driven primarily by infused pre-rolls, which grew 125% [13] Market Data and Key Metrics Changes - International shipments reached $18.9 million in fiscal '23, an increase of 25% from $15.1 million in 2022, despite a slowdown in Q3 due to new testing requirements in Israel [32] - The company harvested approximately 28,000 kilos of flower during Q4 fiscal '23 compared to 16,000 kilos in Q4 2022, representing a 74% increase [40] Company Strategy and Development Direction - The company aims to establish itself as a leader in seed-based cannabis production, planning to convert 30% of its garden to seed-based by the end of fiscal 2024 [22] - A strategic investment in Greentank for exclusive access to revolutionary hardware is expected to enhance the company's vape product offerings [23] - The company is focused on expanding its pre-roll share while optimizing production to improve margins in fiscal 2024 [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the Canadian cannabis industry is facing high excise taxes and restrictive regulations, leading to operational challenges for many licensed producers (LPs) [70] - The company anticipates that the introduction of THCV in various formats will help familiarize this novel cannabinoid for Canadian consumers, with growing awareness already noted [20] - Management expressed confidence in achieving free cash flow positivity in fiscal 2024, supported by improved production efficiencies and international sales growth [67] Other Important Information - The company has a strong balance sheet with unrestricted cash of $33.9 million and negligible debt as of September 30, 2023 [66] - The company is undergoing an audit for EU GMP certification, which is expected to facilitate international shipments to Germany and the U.K. in the back half of fiscal 2024 [94] Q&A Session Summary Question: Can you help quantify the rank order of factors impacting gross margin pressure? - Management indicated that international sales are the highest margin opportunity, and they are working to diversify sales across more countries to avoid lumpy margins [79] Question: What is the focus of the Jupiter initiative regarding international opportunities? - The company plans to focus 60% to 75% of the Jupiter investment on the U.S. market, with ongoing efforts to develop relationships in potential markets [84] Question: Does the guidance for free cash flow rely on international growth? - Management confirmed that international sales growth is a key driver for achieving free cash flow positivity, with plans to expand into new countries [93]

Organigram Holdings Inc. (NASDAQ:OGI) Q3 2023 Earnings Conference Call July 14, 2023 8:00 AM ET Company Participants Max Schwartz - Director, IR Beena Goldenberg - CEO Tim Emberg - Chief Commercial Officer Derrick West - CFO Conference Call Participants Tamy Chen - BMO Frederico Gomes - ATB Capital Markets Aaron Grey - Alliance Global Partners Andrew Partheniou - Stifel GMP Ty Collin - Eight Capital Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would li ...

INTRODUCTION This Management's Discussion and Analysis dated July 13, 2023 (this "MD&A"), should be read in conjunction with the unaudited condensed consolidated interim financial statements (the "Interim Financial Statements") of Organigram Holdings Inc. (the "Company" or "Organigram") for the three and nine months ended May 31, 2023 ("Q3 Fiscal 2023") and the audited annual consolidated financial statements for the year ended August 31, 2022 (the "Annual Financial Statements" together with the Interim Fin ...

Organigram Holdings Inc. (NASDAQ:OGI) Q2 2023 Results Conference Call April 12, 2023 8:00 AM ET Company Participants Max Schwartz - Director, IR Beena Goldenberg - CEO Derrick West - CFO Conference Call Participants Andrew Partheniou - Stifel GMP Tamy Chen - BMO Capital Markets Frederico Gomes - ATB Capital Markets Aaron Grey - Alliance Global Partners Michael Freeman - Raymond James Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome ev ...

INTRODUCTION Financial information in this MD&A is based on the Interim Financial Statements of the Company, and has been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"), unless otherwise stated. All financial information in this MD&A is expressed in thousands of Canadian dollars ("$"), except for share and per share calculations, references to $ millions and $ billions, per gram ("g") or kilogram ...

Organigram Holdings Inc. (NASDAQ:OGI) Q1 2023 Results Conference Call January 12, 2023 8:00 AM ET Company Participants Craig MacPhail - IR, NATIONAL Capital Markets Beena Goldenberg - Chief Executive Officer Derrick West - Chief Financial Officer Conference Call Participants Andrew Partheniou - Stifel Aaron Grey - Alliance Global Partners Tamy Chen - BMO Capital Markets Ty Collin - Eight Capital Michael Freeman - Raymond James Matt Bottomley - Canaccord Genuity Operator Good morning. My name is Rob, and I w ...

This Management's Discussion and Analysis dated January 11, 2023 (this "MD&A"), should be read in conjunction with the unaudited condensed consolidated interim financial statements (the "Interim Financial Statements") of Organigram Holdings Inc. (the "Company" or "Organigram") for the three months ended November 30, 2022 ("Q1 Fiscal 2023") and the audited annual consolidated financial statements for the year ended August 31, 2022 (the "Annual Financial Statements"), including the accompanying notes thereto. ...

👍ORGANIGRAM INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) Q4 Fiscal 2022 11 | 29 | 22 1 CAUTIONARY STATEMENT This document is current as of November 28, 2022, except where otherwise stated. The information contained in this presentation is provided by Organigram Holdings Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of th ...

OrganiGram Holdings Inc. (NASDAQ:OGI) Q4 2022 Results Conference Call November 29, 2022 8:00 AM ET Company Participants Craig MacPhail - Group Director, NATIONAL Capital Markets Beena Goldenberg - Chief Executive Officer Derrick West - Chief Financial Officer Conference Call Participants Tamy Chen - BMO Capital Markets Ty Collin - Eight Capital Aaron Grey - Alliance Global Partners Andrew Partheniou - Stifel Matt Bottomley - Canaccord Genuity Michael Freeman - Raymond James Frederico Gomes - ATB Operator Go ...